Figure 1.

Type I Interferon Signaling Promotes Lung Pathology following Lethal SARS-CoV Infection

(A and B) Percentage of initial weight (A) and survival (B) of mice infected with SARS-CoV.

(C) Clinical scores determined at days 3 and 5 p.i.

(D) SARS-CoV titers in the lungs as determined by plaque assay (ND, not determined).

(E) Gross lung pathology at days 3 and 5 p.i.

(F) Microscopic changes in the lungs of naive and SARS-CoV-challenged mice at day 5 p.i.

(G and H) Weight curves (G) and survival (H) of SARS-CoV infected anti-IFNAR or control (MOPC21) antibody treated mice.

Data are representative of 2–3 independent experiments with 4–5 mice/group. Data in (A), (C), and (D) are represented as ±SEM. ^∗p < 0.05, ^∗∗p < 0.01, and ^∗∗∗p < 0.001. Gross and histopathology results are derived from 4–5 mice/group. See also Figures S1 and S2.